Since only about 40% of malignant tumours can be eradicated by surgery or radiotherapy and only a few particular neoplasms destroyed by chemotherapy, there are pressing reasons why a complementary weapon for the treatment of cancer should be found. The fact that chemotherapy is effective only in tumours which seem to induce intense immune reactions, such as placental choriocarcinoma (Math6, Dausset, et al., 1964; Amiel et al., 1967) and Burkitt tumour (Klein et al., 1966) , has focused attention on the development of immunological treatment.
A further reason which indicates the importance of an immunological approach to the treatment of cancer, in respect of both prevention and cure (Hamilton Fairley, 1969) , is that tumour cells carry new antigens which are specific to each individual tumour-in the case of chemically induced tumours -and to each individual virus-in the case of tumours that are virally induced. Some experimental findings have indicated that these antigens are not peculiar to neoplastic cells and that they may be present in normal cells in which a chemical carcinogen or a virus has penetrated but not caused malignancy (Mathe, 1968a) . Furthermore, certain animals have an immunological tolerance to tumours, particularly when a carcinogenic agent is introduced into the animal during or before the neonatal period (Klein and Klein, 1965 ). An immune insufficiency may frequently occur in human patients with cancer (Schneider, 1969) and in animals with a variety of different tumours. This insufficiency has also been observed during the preleukaemic period in strains of mice which have a high incidence of spontaneous leukaemia (Dore et al., 1969; Schneider et at., 1969) ; and in human patients it can be increased or induced by some types of treatment-in particular by certain forms of chemotherapy (Schneider, 1968) . Moreover, antibodies which do not fix complement and which could facilitate the growth of a tumour can be produced in patients with cancer.
This phenomenon of immunological enhancement, which has mainly been demonstrated and studied in animals, should be given serious consideration in man, as it may be the most probable explanation for the correlation that we have observed in cases of placental choriocarcinoma between the frequency of serum agglutinins, the tolerance of a skin graft from the father during pregnancy, and the prognosis of the individual patient with this tumour (Math6, Dausset et al., 1964 ; Amiel et al., 1967 (Schneider, 1968 (Hrask et al., 1968; Mathe, Nouza et al., 1969) . We are now testing the therapeutic effects of extracts of thymus in man. OrbachArbouys (1968a OrbachArbouys ( , 1968b OrbachArbouys ( , 1968c Amiel, 1967) . The use of such a serum for the treatment of lymphatic leukaemia in mice gave variable and unpredictable results; a rabbit anti-mouse lymphocyte serum was ineffective against the L 1210 leukaemia but could completely eradicate the E &T G2 leukaemia, if fewer than 10,000 leukaemic cells were transplanted (Pouillart and Mathe, 1969) Mathe, Amiel, and Niemetz, 1962; Mathe, Schwarzenberg, and Lapeyraque, 1968) ; on those with AkR spontaneous leukaemia (Mathe and Bernard, 1958 ;  Mathe, Amiel, and Bernard, 1960) ; and on those with the Charlotte Friend virus leukaemia (Math6, Amiel, and Friend, 1962; Math6 and Amiel, 1964) . These experiments have shown the antileukaemic effects of a bone-marrow graft on the leukaemic cells of a recipient if the donor of the bone marrow is immunized with a leukaemogenic virus. In this case the marrow from the donor animal can exert both an antileukaemic effect on a leukaemia induced in the recipient by this virus and an antiviral effect on the leukaemogeneic virus.
Finally, we hope that if this virus is not completely eradicated and if it is not genetically compatible with the tissues of the donor (as is the case with certain leukaemogeneic viruses in mice which can induce leukaemia only in particular strains of mice) the allograft bone marrow will not induce a new leukaemia arising from these donor cells. This experiment has also indicated the difficulty of deriving benefit from this type of immunotherapy on account of the reaction of the graft against the antigens of the host. Such a reaction gives rise to the severe signs and symptoms which have been collectively called4 " the graft-versus-host disease," which is particularly severe in man, especially if the recipient has been pretreated by total body irradiation, the only procedure in use until about a year ago. Under these circumstances the sequelae of irradiation in addition to this graft-versus-host disease can cause a secondary disease that is often lethal.
The incidence of this secondary disease (or syndrome) and our experience with the allogeneic bone marrow grafting in man Mathe, Amiel, et al., 1963 , 1965 are summarized in Table I . The positive (Seman and Sernan, 1961) Sex chromosomes (Math6, Amiel, et al., 1963) Groups of immunoglobulins (Inv) (Mathl, Amiel, et al., 1963) Specific immune tolerance based on the chimerism (Math, Amiel, et al., 1963) in four patients (Fig. 1) (Mathe, Amiel, and Schwarzenberg, 1968 The clinical and histological signs of secondary disease closely resembling that which follows allogeneic bone marrow grafting occur after white-cell transfusion as a form of sympwtomatic treatment, particularly for infections complicating agranulocytosis (Schwarzenberg et al., 1965) . This observation led us to think that a graft-versus-host reaction could occur in a patient who had not been irradiated, and we therefore attempted to obtain an antileukaemic effect from this reaction. We have treated patients suffering from acute leukaemia who had become resistant to all the available forms of chemotherapy with transfusions of white cells. As the signs of a graft-versushost reaction appeared only when many leucocytes were transfused, we first used patients with chronic myeloid leukaemia as donors in order to obtain this large number of cells. We have now treated 21 patients, all of whom were resistant to every available form of chemotherapy, with this form of leucocyte transfusion . Of these, 10 had remissions, of which seven were complete (Fig. 2) . In all the patients (except one who was also being treated with vincristine and had no previous resistance to this drug) the antileukaemic effect may undoubtedly be attributed to the transfusions of leucocytes. The antileukaemic effect correlated well with the clinical signs and symptoms of a graft-versus-host reaction (Table III) and strongly suggested that they were causally related.
We have now acquired the use of an I.B.M. continuous flow machine for the separation of white cells, which enables us to obtain easily up to 1 5 x 101 lymphocytes from a normal donor at one session . Using these The preventive effect of adjuvants (Old et al., 1959 ; Biozzi et at., 1959; Amiel, 1967; Math6 and Pouillart, 1969a) , or of irradiated tumour cells (Glynn et al., 1963; Mathe and Pouillart, 1969b) against grafted tumours has been widely reported. Charlotte Friend (1959) Virus particles have been discovered-sometimes in large numbers-in human leukaemic cells, particularly by Seman and Seman (1968) , and there is evidence that in the blood of 20% of patients with leukaemia antibodies may be found that are active against the patient's own leukaemic cells (Dore et al., 1967) . Nevertheless, it is still too early to contemplate the use of active preventive immunotherapy in man.
Using the L 1210 leukaemia as a simple model (Math6, 1968b; Math6 and Pouillart, 1969b) , we have shown that treatment of animals with donor-irradiated leukaemic cells or by B.C.G. applied 24 hours after the graft of the leukaemia delays and reduces the mortality, but only if the number of living leukaemic cells that were grafted was not more than 105 ; irradiated leukaemic cells were more efficient than the B.C.G., and the combination of the two of them was more efficient than using irradiated cells alone. The irradiated cells, and especially with B.C.G., were still effective if they were given four days after grafting the leukaemia. After leukaemic cells have been transplanted they first grow fast and then slowly.
Immunotherapy acts only on this slow phase, sometimes slowing it down or stopping growth, or sometimes killing the graft entirely, so that the animal is cured. Relapses (2 
Results
All the 10 control patients have relapsed. The average duration of the remission after the arrest of chemotherapy was 66 days; the median was somewhere between the 70th and 77th days, the limits being 30 and 130 days. On the other hand, 130 days after stopping chemotherapy (the date of the relapse of the last control patient) only 9 out of the 20 patients given immunotherapy had relapsed. The difference between these two groups is highly significant (X2=618, P=0-02). On 1 June 1969 four other patients had relapsed. Analysis of the relapses in these treated patients suggests that most of them occur at an early stage. Thus nine occurred before the 100th day and five before the 30th day. This is comparable with the experimental observations, and suggests that the number of tumour cells left after chemotherapy was greater than the maximum number that could be controlled by active immunotherapy. Four relapses were of late onset; one occurred at the 210th day, one at the 315th day, and another at the 950th day.
This feature is comparable with those exceptional late relapses which we had noted in our experiments with mice. In the fourth patient the relapse occurred at the 324th day; he was an infant in whom the B.C.G. treatment had been stopped 44 days previously because of the recrudescence of a severe phlyctenular keratoconjunctivitis. Seven patients are still in remission more than one year since stopping chemotherapy, in four it is more than two years, and in. one more than three years. Hence there seems to be no reason for not continuing immunotherapy indefinitely. Fig. 3 shows the actuarial curves, demonstrating differences between the groups submitted to immunotherapy and our groups of controls; and indicates that though the median length of remission after stopping chemotherapy in our patients given immunotherapy is about the same as that in those given intensive chemotherapy, the shape of the curve of these two e*A_ groups is quite different. That of the patients given immunotherapy tends to straighten out and continue as a plateau. There was no significant difference between the group given B.C.G. (five relapses out of eight patients, in one of whom treatment was stopped), those given leukaemic cells alone (three relapses in five patients), and those given both forms of immunotherapy.
Hence this trial proves that active immunotherapy may be successful in controlling acute lymphoblastic leukaemia. We now plan to apply this method to patients treated by chemotherapy to diminish the number of leukaemic cells even more than was possible using the sequential chemotherapy that we employed in this first trial.
